Value
4.5/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
| Analyst target | 7.5 |
ABCL · Why this verdict
Why AbCellera Biologics (ABCL) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.5/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Revenue has expanded 96% year-over-year, positioning the company as the growth leader among biotechnology peers; if that trajectory continues, the valuation gap implied by the analyst consensus may begin to close. Growth breakdown | Revenue growth sustained above 50% year-over-year in each of the next 2 quarterly reports. | →Stable |
| CounterFree cash flow is negative at roughly 144% of revenue, meaning growth is being purchased at the cost of cash reserves; if capital markets tighten or dilutive financing is required, the top-line rate may decelerate before generating any economic return. | ||
The company has beaten EPS estimates in 3 of the last 4 quarters, most recently by 29%, with an average positive surprise of approximately 30%, suggesting management is consistently delivering above its own guidance cadence. Earnings | EPS surprise remains positive in each of the next 2 quarterly earnings releases. | →Stable |
| CounterOne miss of -17% in the third most recent quarter demonstrates the beat pattern is not unbroken; with losses still running at -$0.14 per share in the most recent period, any step-up in operating costs can quickly flip a projected beat into a miss. | ||
Free cash flow is negative at approximately 144% of revenue, meaning the business is consuming more cash than it generates; this cash burn creates a hard ceiling on business quality metrics that cannot lift until cash conversion fundamentally improves. Quality breakdown | Free cash flow loss narrows materially, with the FCF-to-revenue ratio approaching breakeven within 4 quarters. | →Stable |
| CounterFor a company growing revenue at 96% per year, negative free cash flow during a scaling phase is not unusual; if the growth rate sustains, operating leverage may bring cash conversion toward positive territory within the medium term. | ||
Short interest stands at 20% of the float — an elevated level for a small-cap biotechnology name — signaling persistent market skepticism that suppresses the stock's ability to re-rate even as fundamentals improve. Key risks | Short interest declines below 10%, reflecting a meaningful reduction in the bear conviction overhang. | →Stable |
| CounterConcentrated short positions can reverse sharply on positive news; if earnings execution continues and the cash burn trajectory improves, a rapid short-covering episode could amplify any fundamental re-rating beyond what the fundamentals alone would warrant. | ||
Revenue has expanded 96% year-over-year, positioning the company as the growth leader among biotechnology peers; if that trajectory continues, the valuation gap implied by the analyst consensus may begin to close.
→StableGrowth breakdown
- Expectation
- Revenue growth sustained above 50% year-over-year in each of the next 2 quarterly reports.
CounterFree cash flow is negative at roughly 144% of revenue, meaning growth is being purchased at the cost of cash reserves; if capital markets tighten or dilutive financing is required, the top-line rate may decelerate before generating any economic return.
The company has beaten EPS estimates in 3 of the last 4 quarters, most recently by 29%, with an average positive surprise of approximately 30%, suggesting management is consistently delivering above its own guidance cadence.
→StableEarnings
- Expectation
- EPS surprise remains positive in each of the next 2 quarterly earnings releases.
CounterOne miss of -17% in the third most recent quarter demonstrates the beat pattern is not unbroken; with losses still running at -$0.14 per share in the most recent period, any step-up in operating costs can quickly flip a projected beat into a miss.
Free cash flow is negative at approximately 144% of revenue, meaning the business is consuming more cash than it generates; this cash burn creates a hard ceiling on business quality metrics that cannot lift until cash conversion fundamentally improves.
→StableQuality breakdown
- Expectation
- Free cash flow loss narrows materially, with the FCF-to-revenue ratio approaching breakeven within 4 quarters.
CounterFor a company growing revenue at 96% per year, negative free cash flow during a scaling phase is not unusual; if the growth rate sustains, operating leverage may bring cash conversion toward positive territory within the medium term.
Short interest stands at 20% of the float — an elevated level for a small-cap biotechnology name — signaling persistent market skepticism that suppresses the stock's ability to re-rate even as fundamentals improve.
→StableKey risks
- Expectation
- Short interest declines below 10%, reflecting a meaningful reduction in the bear conviction overhang.
CounterConcentrated short positions can reverse sharply on positive news; if earnings execution continues and the cash burn trajectory improves, a rapid short-covering episode could amplify any fundamental re-rating beyond what the fundamentals alone would warrant.
TrendMatrix Research · core thesis
Engine thesis — one sentence
AbCellera Biologics has delivered 96% year-over-year revenue growth and beaten EPS estimates in 3 of the last 4 quarters, but the thesis hinges on whether the current cash burn — negative free cash flow at roughly 144% of revenue — narrows fast enough to allow quality metrics to recover; until it does, the stock remains speculative despite a favorable long-term risk/reward geometry.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
2.5/10data confidence 86%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 5.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -144% of revenue
- ▸Quality concerns
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 96% YoY
Momentum
4.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.3 |
| MACD | 9.6 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Overbought (RSI 74)
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.5 |
| Analyst rating | 5.0 |
| Price target | 9.0 |
- ▸Analyst upside: 36%
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Negligible insider buying — $95,400 (0.004% of mkt cap)
- ▸Institutions accumulating
Peer rank
3.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 1.8 |
| quality rank | 3.7 |
| growth rank | 8.1 |
- ▸Industry growth leader
Technical
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.2 |
| support resistance | 2.3 |
| 52w position | 8.1 |
| gap | 3.0 |
- ▸Extreme gap up (5.8%) - may pull back
Risk (lower is worse)
4.1/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.6 |
| days to cover | 4.4 |
| volatility | 0.0 |
| put call | 8.1 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 6.4 |
| debt equity | 9.4 |
- ▸High short interest justified: 19%
- ▸High IV: 125%
- ▸Above max pain $1
Catalyst
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 5.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (5)
- MOMENTUM:4.8>=4.5
- INSIDER:OK
- EARNINGS_PROXIMITY:32d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:1.2<1.5@spot
Warning (2)
- MOMENTUM:4.8<5.5 (soft — BUY_NOW allowed but watch)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
1.23
Upside
+18.5%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Growth at 10.0 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:1.2<1.5@spot.
The strongest dimensions are Growth at 10.0, Insider at 7.3, and Sentiment at 6.7; the weakest are Quality at 2.5, Peer rank at 3.4, and Technical at 3.9. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of 1.23 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Industry Leading Revenue Growth
Trip ifRevenue growth falls below 50% year-over-year for 2 consecutive quarters.
- P2Earnings Beat Consistency
Trip ifEPS surprise stays below 0% for 2 consecutive quarters.
- P3Negative Fcf Quality Ceiling
Trip ifFree cash flow turns positive and the FCF-to-revenue ratio rises above 0% for 2 consecutive quarters.
- P4High Short Interest Overhang
Trip ifShort interest falls below 10% of float for 2 consecutive months.